Scalper1 News
Gene-sequencing giant Illumina (ILMN) pre-announced Q3 revenue and full-year guidance that missed estimates Monday, sending its stock tumbling after hours. Illumina said Q3 revenue totaled $550 million, up 14% from the year-earlier quarter but $19 million short of analysts’ consensus, according to Thomson Reuters. The company also said it expects Q4 revenue of $570 million, up 11% from last year but $32 million shy of Wall Street’s estimate. That Scalper1 News
Scalper1 News